Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Warnings Not To Give Young Children Cough/Cold OTCs Still Go Unheeded

This article was originally published in The Tan Sheet

Executive Summary

Four in 10 parents said they administered OTC cough and cold products to children younger than 4 years even though labeling says not to use in this age group, according to a national poll. The finding suggests more education is necessary to reduce confusion and noncompliance.

You may also be interested in...



McNeil Recalls Liquid Infants’ Tylenol With Dosing Device Problem

McNeil Consumer Healthcare recalls an Infants’ Tylenol product that returned to market in November, after receiving consumer complaints about a problem with the SimpleMeasure dosing device system. The recall marks a misstep in the J&J subsidiary’s comeback from OTC quality control issues.

Campaign Targets Unsupervised Pediatric Drug Ingestion

The Consumer Healthcare Products Association, the Centers for Disease Control and Prevention and a public-private safe-medication initiative launch the “Up and Away and Out of Sight” campaign to educate caregivers about how to stop curious children from consuming drugs without supervision.

Parents Continue To Give Cough/Cold OTCs To Children Under 2 – Survey

A majority of U.S. parents and some pediatricians fail to heed FDA and drug industry warnings not to give OTC cough and cold medicines to children under 2, according to a recent poll.

Related Content

Topics

Related Companies

UsernamePublicRestriction

Register

PS106436

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel